Pulmonary hypertension in children: A historical overview

Pediatric Critical Care Medicine

Volumn 11, Issue SUPPL. 2, 2010, Pages

  Abman, Steven H ^a  

^a Children's Hospital Colorado   (United States)

Author keywords

Bronchopulmonary dysplasia; Congenital heart disease; Endothelin; Lung development; Nitric oxide; Phosphodiesterase inhibitors; Prostacyclin; Pulmonary hypertension

Indexed keywords

BLOOD VESSEL WALL; CHILD; CONFERENCE PAPER; DEATH; DISEASE CLASSIFICATION; DISEASE SEVERITY; GENETIC ANALYSIS; HEART OUTPUT; HEART RIGHT VENTRICLE FAILURE; HUMAN; LUNG VASCULAR RESISTANCE; OUTCOME ASSESSMENT; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; QUALITY OF LIFE; SURVIVAL RATE; TREATMENT PLANNING; WORLD HEALTH ORGANIZATION;

EID: 77949470581     PISSN: 15297535     EISSN: None     Source Type: Journal    
DOI: 10.1097/PCC.0b013e3181c765f3     Document Type: Conference Paper

References (36)

1. D'Alonzo GE, Barst RE, Ayres SM, et al: Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med 1991; 115: 343-349
2. McLaughlin VV, Shillington A, Rich S: Survival in primary pulmonary hypertension:The impact of epoprostenol therapy. Circulation 2002; 106:1477-1482
3. Simonneau G, Galie N, Rubin LJ, et al: Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004; 43(Suppl S): S5-S12
4. Rabinovitch M: Molecular pathogenesis of pulmonary arterial hypertension. J Clin Invest 2008; 118:2372-2379
5. Chambers CD, Hernandez-Diaz S, van Marter LJ, et al: Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension. N Engl J Med 2006; 354:579-587
6. Jakkula M, Le Cras TD, Gebb S, et al: Inhibition of angiogenesis decreases alveolarization in the developing rat lung. Am J Physiol Lung Cell Mol Physiol 2000; 279:L600-L609
7. Kasahara Y, Tuder RM, Taraseviciene-Stewart L, et al: Inhibition of VEGF receptors causes lung cell apoptosis and emphysema. J Clin Invest 2000; 106:1311-1319
8. Tuder RM, Groves B, Badesch D, et al. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol 1994; 144:275-285
9. Sandoval J, Bauerle O, Gomez A, et al: Primary pulmonary hypertension in children: Clinical characterization and survival. J Am Coll Cardiol 1995; 25:466-474
10. International PPH Consortium, Lane KB, Machado RD, et al: Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. Nat Genet 2000; 26:81-84
11. Deng Z, Morse JH, Slager SL, et al: Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 2000; 67:737-744
12. Newman JH, Phillips JA, Loyd JE: The enigma of pulmonary arterial hypertension: New insights from genetic studies. Ann Intern Med 2008; 148:278-283
13. Sztrymf B, Coulet F, Girard B, et al: Clinical outcomes of pulmonary artery hypertension in carriers of BMPR2 mutation. Am J Respir Crit Care Med 2008; 177:1377-1383
14. Grunig E, Koehler R, Miltenberger-Miltenyi G, et al: Primary pulmonary hypertension in children may have a different genetic background than adults. Pediatr Res 2004; 56: 571-578
15. Harrison RE, Berger R, Haworth SG, et al: Transforming growth factor-beta receptor mutations and pulmonary arterial hypertension in childhood. Circulation 2005; 111: 435-441
16. Rosenzweig EB, Morse JH, Knowles JA, et al: Clinical implications of determining BMPR2 mutation status in a large cohort of children and adults with pulmonary arterial hypertension. J Heart Lung Transplant 2008; 27: 668-674
17. Trembath RC, Thomson JR, Machado RD, et al: Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N Engl J Med 2001; 345:325-334
18. Eddahibi S, Humbert M, Fadel E, et al: Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle cell hyperplasia in primary pulmonary hypertension. J Clin Invest 2001; 108: 1141-1145
19. Moncada S, Gryglewski R, Bunting S, et al: An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976; 263:663-665
20. Higgenbottam TW, Wheeldon D, Wells FC, et al: Long term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin). Lancet 1984; 1:1046-1047
21. Tuder RM, Cool CD, Geraci MW, et al: Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 1999; 159:1925-1932
22. Barst RJ, Rubin LJ, Long WA, et al: A com- parison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hyperetnsion. N Engl J Med 1996; 334:296-301
23. Tapson VF, Gomberg-Maitland M, McLaughlin VV, et al: Safety and efficacy of IV treprostenil for pulmonary arterial hypertension: A prospective, multicenter open label 12 week trial. Chest 2006; 129:683-688
24. Hoeper MM, Schwarze M, Ehlerding S, et al: Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med 2000; 342:1866-1870
25. Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure. The Neonatal Inhaled Nitric Oxide Study Group. N Engl J Med 1997; 336: 597-604
26. Roberts JD, Fineman J, Morin FC III, et al: Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. N Engl J Med 1997; 336:605-610
27. Clark RH, Kueser TJ, Walker MW, et al: Lowdose inhaled NO treatment of PPHN. N Engl J Med 2000; 342:469-474
28. Galie N, Ghofrani HA, Tobicki A, et al: Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353: 2148-2157
29. Yanagisawa M, Kurihara H, Kimura S, et al: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332:411-415
30. Hickey KA, Rubani G, Paul RJ, et al: Characterization of a coronary vasoconstrictor produced by cultured endothelial cells. Am J Physiol 1985; 248:C550-C556
31. Kedzierski RM, Yanagisawa M: Endothelin system: The double-edged sword in health and disease. Annu Rev Pharmacol 2001; 41: 851-876
32. Giaid A, Yanagisawa M, Langleben D, et al: Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993; 328:1732-1739
33. Stewart DJ, Levy RD, Cernacek P, et al: Increased plasma endothelin-1 in pulmonary hypertension: Marker or mediator of disease? Ann Intern Med 1991; 114:464-469
34. Rubin LJ, Badesch DB, Barst RJ, et al: Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896-903
35. Badesch DB, Abman SH, Ahearn G, et al: Medical therapies for pulmonary arterial hypertension: ACCP evidence based guidelines for clinical practice. Chest 2004; 126: 35S-37S
36. Rosenzweig EB, Ivy DD, Widlitz A, et al: Effects of long-term bosentan in children with pulmonary arterial hypertension. J Am Coll Cardiol 2005; 46:697-704